Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 12:28 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,228 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: TBL 12 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Dose Ethnobridging PK Study in Healthy Subjects

NCT03750565
View directory record Official record
Conditions
Inflammatory Bowel Diseases, IBD
Interventions
TD-1473 - Dose A, TD-1473 - Dose B, TD-1473 - Dose C, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Nov 3, 2026, 12:28 AM EST
Terminated Phase 3 Interventional Results available

A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).

NCT05227209
View directory record Official record
Conditions
Depressive Episodes, Bipolar I Depression
Interventions
SEP-4199 CR
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
Huntsville, Alabama • Anaheim, California • Imperial, California + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Nov 3, 2026, 12:28 AM EST
Completed Phase 2 Interventional Results available

A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia

NCT00088621
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone 80mg tablet
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
21
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Cerritos, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Nov 3, 2026, 12:28 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial to Evaluate MK-4208/Embibatinib in Healthy Adult Participants (MK-4208-001/Embibatinib-1014)

NCT07838987
View directory record Official record
Conditions
Healthy
Interventions
Embibatinib, Rabeprazole, Midazolam, Digoxin, Pravastatin, Montelukast, Omeprazole, Itraconazole, Warfarin, Rosuvastatin, Bosentan, Quinidine
Drug
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 3, 2026, 12:28 AM EST
Recruiting Phase 1Phase 2 Interventional

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

NCT04774393
View directory record Official record
Conditions
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Decitabine and Cedazuridine, Enasidenib, Ivosidenib, Venetoclax
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Nov 3, 2026, 12:28 AM EST
Terminated Phase 2 Interventional Results available

Reduce Crohn's-Associated Diarrhea With Sodium Channel Therapy

NCT04456517
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Disease
Interventions
Ranolazine, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Nov 3, 2026, 12:28 AM EST
Completed Phase 3 Interventional Results available

A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed

NCT04542070
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir Tablets, Cabotegravir Injectable Suspension (CAB LA), Rilpivirine Tablets, Rilpivirine Injectable Suspension (RPV LA), BIKTARVY Tablets (BIK)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
687 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
41
States / cities
Bakersfield, California • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2024 · Synced Nov 3, 2026, 12:28 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Cellular Pharmacology of F-TAF in Dried Blood Spots

NCT02962739
View directory record Official record
Conditions
Healthy Volunteers
Interventions
emtricitabine 200 mg/tenofovir alafenamide 25mg
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 59 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Nov 3, 2026, 12:28 AM EST
Completed Phase 2 Interventional Results available

Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata

NCT03811912
View directory record Official record
Conditions
Alopecia Areata
Interventions
CTP-543, CTP-543 Matching Placebo
Drug
Lead sponsor
Concert Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
10
States / cities
Irvine, California • San Francisco, California • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2022 · Synced Nov 3, 2026, 12:28 AM EST
Not listed Phase 2 Interventional

StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study

NCT02082054
View directory record Official record
Conditions
Rhinitis, Seasonal, Allergic
Interventions
PSE 120 mg, CM 8 mg, Atr 0.36 mg, PSE 120 mg, CM 8 mg, Atr 0.24 mg, PSE 120 mg, CM 8 mg, Atr 0.12 mg, PSE 120 mg, CM 8 mg, Atropine 0.24 mg
Drug
Lead sponsor
Magna Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 60 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Stockbridge, Georgia • Louisville, Kentucky • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 30, 2014 · Synced Nov 3, 2026, 12:28 AM EST
Completed Phase 2Phase 3 Interventional

Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole

NCT03440359
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Progesterone Vaginal Gel 8%, Letrozole Oral Tablet, pelvic ultrasound, Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe, Intrauterine insemination or timed intercourse
Drug · Diagnostic Test · Other
Lead sponsor
Eastern Virginia Medical School
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 26, 2018 · Synced Nov 3, 2026, 12:28 AM EST
Terminated Phase 2 Interventional Results available

A Study of ABI-H0731 + Nucleos(t)Ide as Finite Treatment for Chronic Hepatitis B Patients

NCT03780543
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
standard of care (SOC) Nucleoside reverse transcriptase inhibitor (NrtI)
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 71 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Beverly Hills, California • Coronado, California • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Nov 3, 2026, 12:28 AM EST
Completed Phase 3 Interventional Results available

Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

NCT03118843
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL/VOX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • Rialto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Nov 3, 2026, 12:28 AM EST
Completed Phase 2 Interventional Results available

Effect of LIK066 on Reduction of Fatty Content in Livers of Obese Patients

NCT03205150
View directory record Official record
Conditions
Obese Patients With Non-alcoholic Steatohepatitis (NASH)
Interventions
LIK066, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
4
States / cities
Baton Rouge, Louisiana • St Louis, Missouri • Knoxville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Nov 3, 2026, 12:28 AM EST
Completed Phase 3 Interventional Results available

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

NCT03541174
View directory record Official record
Conditions
Resistant Hypertension
Interventions
Aprocitentan 12.5 mg, Aprocitentan 25 mg, Placebo
Drug
Lead sponsor
Idorsia Pharmaceuticals Ltd.
Industry
Eligibility
18 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
41
States / cities
Alexander City, Alabama • Inglewood, California • Lincoln, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2023 · Synced Nov 3, 2026, 12:28 AM EST
Completed Phase 1 Interventional Results available

Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

NCT05217537
View directory record Official record
Conditions
Bacterial Infections
Interventions
Omadacycline Injection [Nuzyra], Omadacycline Oral Tablet
Drug
Lead sponsor
Paratek Pharmaceuticals Inc
Industry
Eligibility
8 Years to 17 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Little Rock, Arkansas • Long Beach, California • Orange, California + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Nov 3, 2026, 12:28 AM EST
Completed Phase 4 Interventional Results available

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure

NCT03030222
View directory record Official record
Conditions
Heart Failure
Interventions
Empagliflozin 10 mg Tab, Placebo Oral Tablet
Drug
Lead sponsor
Saint Luke's Health System
Other
Eligibility
19 Years to 119 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
10
States / cities
Los Angeles, California • Jacksonville, Florida • Evanston, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Nov 3, 2026, 12:28 AM EST
Withdrawn Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease

NCT05082571
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
4 Months to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Nov 3, 2026, 12:28 AM EST
Terminated Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

NCT01368536
View directory record Official record
Conditions
Hypertension, Stage 2 Hypertension, Diabetes
Interventions
Valturna, Amlodipine, Chlorthalidone, Placebo of Valturna Tablet, Placebo Capsule
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
95
States / cities
Athens, Alabama • Florence, Alabama • Huntsville, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Mar 21, 2013 · Synced Nov 3, 2026, 12:28 AM EST
Completed Phase 3 Interventional Results available

Multi-Center, Randomized, Open-Label Study of G/P +/- RBV for NS5A + SOF Previously Treated GT1 HCV Subjects

NCT03092375
View directory record Official record
Conditions
Hepatitis C, HCV
Interventions
Glecaprevir/Pibrentasvir (G/P) 300mg/120mg, Ribavirin 200Mg Tablet
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
177 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
31
States / cities
Palo Alto, California • San Francisco, California • Washington D.C., District of Columbia + 22 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2020 · Synced Nov 3, 2026, 12:28 AM EST
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus

NCT03617536
View directory record Official record
Conditions
Chronic Kidney Diseases, Pruritus
Interventions
CR845 0.25 mg Oral Tablet, CR845 0.5 mg Oral Tablet, CR845 1 mg Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
60
States / cities
Birmingham, Alabama • Florence, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Nov 3, 2026, 12:28 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study Of PF-04171327 And Prednisone On Carbohydrate Metabolism

NCT01199900
View directory record Official record
Conditions
Healthy
Interventions
PF-04171327, Prednisone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Kalamazoo, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 17, 2010 · Synced Nov 3, 2026, 12:28 AM EST
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of GSK1605786 on Hepatic Cytochrome P450, and BCRP and OATP1B1 Transport in Healthy Adult Subjects

NCT01489943
View directory record Official record
Conditions
Crohn's Disease
Interventions
GSK1605786 500 mg, Midazolam 3 mg, Pioglitazone 15 mg, Omeprazole 40 mg, Rosuvastatin 10 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Nov 3, 2026, 12:28 AM EST
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Actual Use and Compliance Study Of Ibuprofen 600 Mg Immediate Release/Extended Release Tablets In At-Risk OTC Consumers

NCT03722238
View directory record Official record
Conditions
Pain
Interventions
Ibuprofen 600 mg Immediate Release/Extended Release Caplet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
613 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
27
States / cities
Hoover, Alabama • Mesa, Arizona • Tucson, Arizona + 24 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2021 · Synced Nov 3, 2026, 12:28 AM EST